USRE43431EExpiredUtility

Quinazoline derivatives and pharmaceutical compositions containing them

97
Assignee: HIMMELSBACH FRANKPriority: Dec 20, 2000Filed: Aug 18, 2009Granted: May 29, 2012
Est. expiryDec 20, 2020(expired)· nominal 20-yr term from priority
A61P 35/00A61P 1/00A61P 17/06C07D 405/12A61P 11/00C07D 239/94
97
PatentIndex Score
37
Cited by
140
References
12
Claims

Abstract

A compound of general formula I wherein: Ra is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; Rb is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and Rc is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

Claims

exact text as granted — not AI-modified
We claim: 
     
       1. A compound of formula I 
       
         
           
           
               
               
           
         
       
       wherein
 R a  is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; 
 R b  is a dimethylamino, N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and 
 R c  is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, 
 or a stereoisomer or physiologically acceptable salt thereof. 
 
     
     
       2. The compound of  claim 1 , wherein Rb is a dimethylamino or a stereoisomer or physiologically acceptable salt thereof. 
     
     
       3. The compound of formula I according to  claim 1 , wherein:
 R a  is a 1-phenylethyl or 3-chloro-4-fluorophenyl group;   R b  is a dimethylamino, N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and   R c  is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetradrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,   or a stereoisomer or physiologically acceptable salt thereof.   
     
     
       4. The compounds of  claim 3 , wherein
 R b  is a dimethylamino,   or a stereoisomer or physiologically acceptable salt thereof.   
     
     
       5. The compounds of  claim 3 , wherein
 R a  is a 3-chloro-4-fluorohenyl group and   R b  is a dimethylamino group,   or a stereoisomer or physiologically acceptable salt thereof.   
     
     
       6. The compound of formula I according to  claim 1 , wherein:
 R a  is a 3-chloro-4-fluorophenyl group;   R b  is a dimethylaminno group; and   R c  is a tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,   or a steroisomer or physiologically acceptable salt thereof.   
     
     
       7. The compound of claim 1, wherein:
 R c  is a tetrahydrofuran-3-yloxy,   or a steroisomer or physiologically acceptable salt thereof.   
     
     
       8. 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-(tetrahydrofuran-3-yl)oxy)quinazoline. 
     
     
       9. A physiologically acceptable salt comprising the combination of the compound according to claim 8 with an organic or inorganic acid. 
     
     
       10. The salt according to claim 9 wherein the acid is hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid. 
     
     
       11. The salt according to claim 10, wherein the acid is maleic acid. 
     
     
       12. 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-(tetrahydrofuran-3-yl)oxy)quinazoline.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.